Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15745067 | 1.00 | GRM2 (0.32) | GRM2PDK2ALOX5APFEN1S1PR1 | |
| SCHEMBL3439575 | 0.92 | PDK2 (0.32) | GRM2PDK2S1PR1S1PR3 | |
| SCHEMBL3439578 | 0.92 | PDK2 (0.32) | GRM2PDK2S1PR1S1PR3 | |
| SCHEMBL3439573 | 0.92 | PDK2 (0.32) | GRM2PDK2S1PR1S1PR3 | |
| SCHEMBL15745163 | 0.90 | — | — | |
| SCHEMBL15745185 | 0.90 | — | — | |
| SCHEMBL13002725 | 0.89 | PDK2 (0.30) | PDK2 | |
| SCHEMBL15744321 | 0.89 | GRM2 (0.35) | GRM2PDK2ALOX5APFEN1S1PR1 | |
| SCHEMBL15745124 | 0.89 | GRM2 (0.35) | GRM2PDK2ALOX5APFEN1S1PR1 | |
| SCHEMBL15744304 | 0.89 | PDK2 (0.37) | GRM2PDK2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365774-B2 | Liquid crystal compound having CF2OCF3 at terminal, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365774-B2 | Liquid crystal compound having CF2OCF3 at terminal, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20140145113-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2OCF3 AT TERMINAL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-05-29 | — | — | US | disclosed |
| US-20140145113-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2OCF3 AT TERMINAL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2735599-A1 | Liquid crystal compound having CF2OCF3 at terminal, liquid crystal composition and liquid crystal display device | JNC Corporation (JP) | 2014-05-28 | — | — | EP | disclosed |
| US-20130184328-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184328-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | GRM2 763/4885PDK2 4614/4885ALOX5AP 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.